TCR2 Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass., Aug. 8, 2017 /PRNewswire/ -- TCR(2) Therapeutics Inc. announced today that its Chief Executive Officer, Garry E. Menzel, Ph.D., will present a corporate overview at the Wedbush PacGrow Healthcare Conference on Wednesday, August 16, 2017 at 12:45PM Eastern Time. The event will be held in New York, NY at Le Parker Meridien.
About TCR(2 )Therapeutics
TCR(2) Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies that utilize the full signaling power of complete T cell receptors (TCR). TCR(2) has developed a unique proprietary TRuC(TM) platform which can reprogram the natural TCR complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. The company has demonstrated superior activity against both hematological and solid tumor targets in preclinical models compared to CAR-T and believes its TRuC(TM)-reprogrammed T cells will serve as a backbone for solid tumor therapies. TCR(2) was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. It has since assembled a world-class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA. For more information, please visit www.tcr2.com.
View original content:http://www.prnewswire.com/news-releases/tcr2-therapeutics-to-present-at-the-2017-wedbush-pacgrow-healthcare-conference-300500625.html
SOURCE TCR2 Therapeutics
